Epigenetic Therapy Targets Endocrine-Resistant Breast Cancer

被引：0
|
作者：
机构：
来源：
Genetic Engineering and Biotechnology News | 2024年 / 44卷 / 04期
关键词：
D O I：
10.1089/gen.44.04.12
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
相关论文
共 50 条
  • [21] Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance
    Junichi Kurebayashi
    Breast Cancer, 2003, 10 (2) : 112 - 119
  • [22] PIK3CA mutations in endocrine-resistant breast cancer
    Schagerholm, Caroline
    Robertson, Stephanie
    Toosi, Hosein
    Sifakis, Emmanouil G.
    Hartman, Johan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [23] Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer
    Huang, Rui
    Faratian, Dana
    Sims, Andrew H.
    Wilson, Danielle
    Thomas, Jeremy S.
    Harrison, David J.
    Langdon, Simon P.
    PLOS ONE, 2014, 9 (04):
  • [24] PIK3CA mutations in endocrine-resistant breast cancer
    Schagerholm, C.
    Robertson, S.
    Holm, B.
    Awier, H.
    Toosi, H.
    Sifakis, E.
    Hartman, J.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S42 - S43
  • [25] Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer
    Seyedi, Sareh
    Teo, Ruthanne
    Foster, Luke
    Saha, Daniel
    Mina, Lida
    Northfelt, Donald
    Anderson, Karen S.
    Shibata, Darryl
    Gatenby, Robert
    Cisneros, Luis H.
    Troan, Brigid
    Anderson, Alexander R. A.
    Maley, Carlo C.
    CANCERS, 2024, 16 (02)
  • [26] Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
    Chen, Jing
    Wan, Runlan
    Li, Qinqin
    Rao, Zhenghuan
    Wang, Yanlin
    Zhang, Lei
    Teichmann, Alexander Tobias
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [27] The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
    Migliaccio, I.
    Biganzoli, L.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 683 - 685
  • [28] Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers
    Ser Yue Loo
    Nicholas L. Syn
    Angele Pei-Fern Koh
    Janet Cheng-Fei Teng
    Amudha Deivasigamani
    Tuan Zea Tan
    Aye Aye Thike
    Shireen Vali
    Shweta Kapoor
    Xiaoyuan Wang
    Jiong Wei Wang
    Puay Hoon Tan
    George W. Yip
    Gautam Sethi
    Ruby Yun-Ju Huang
    Kam Man Hui
    Lingzhi Wang
    Boon Cher Goh
    Alan Prem Kumar
    Cell Death Discovery, 7
  • [29] The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
    Razavi, Pedram
    Chang, Matthew T.
    Xu, Guotai
    Bandlamudi, Chaitanya
    Ross, Dara S.
    Vasan, Neil
    Cai, Yanyan
    Bielski, Craig M.
    Donoghue, Mark T. A.
    Jonsson, Philip
    Penson, Alexander
    Shen, Ronglai
    Pareja, Fresia
    Kundra, Ritika
    Middha, Sumit
    Cheng, Michael L.
    Zehir, Ahmet
    Kandoth, Cyriac
    Patel, Ruchi
    Huberman, Kety
    Smyth, Lillian M.
    Jhaveri, Komal
    Modi, Shanu
    Traina, Tiffany A.
    Dang, Chau
    Zhang, Wen
    Weigelt, Britta
    Li, Bob T.
    Ladanyi, Marc
    Hyman, David M.
    Schultz, Nikolaus
    Robson, Mark E.
    Hudis, Clifford
    Brogi, Edi
    Viale, Agnes
    Norton, Larry
    Dickler, Maura N.
    Berger, Michael F.
    Iacobuzio-Donahue, Christine A.
    Chandarlapaty, Sarat
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Solit, David B.
    Taylor, Barry S.
    Baselga, Jose
    CANCER CELL, 2018, 34 (03) : 427 - +
  • [30] Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer
    Stone, Andrew
    Valdes-Mora, Fatima
    Clark, Susan J.
    EPIGENOMICS, 2013, 5 (06) : 595 - 598
12345